LIDDS AB (publ) (STO:LIDDS)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0430
+0.0040 (10.26%)
May 13, 2025, 5:29 PM CET
-74.78%
Market Cap 5.87M
Revenue (ttm) 32.00K
Net Income (ttm) -4.31M
Shares Out 136.46M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 566,709
Average Volume 198,451
Open 0.0390
Previous Close 0.0390
Day's Range 0.0374 - 0.0498
52-Week Range 0.0304 - 0.2300
Beta 0.23
RSI 43.59
Earnings Date May 6, 2025

About LIDDS AB

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 1
Stock Exchange Nasdaq Stockholm
Ticker Symbol LIDDS
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.